They have a project to develop a polyvalent vaccine for SARS, MERS, and COVID-19. IF they could develop it, they will be the winner of this game by far!
VBIV is breaking out of a symmetrical triangle on 15min within a much larger ascending triangle on 4hr which may be a continuation pattern off of the local price bottom. I expect to see $1.50 within next 3 trading days.
Successful completion of the pivotal Phase 3 program for Sci-B-Vac®, on-track for submission of regulatory approval applications in the U.S., Europe, and Canada expected to begin in Q4 2020 Announcement of pan-coronavirus vaccine candidate targeting COVID-19, SARS, and MERS – human clinical study material expected to be available in Q4 2020 Expanded immunologic,...
VBI Vaccines Inc., a biopharmaceutical company, develops and sells vaccines for the treatment of infectious diseases and immuno-oncology in Israel, the United States, and internationally. The company offers Sci-B-Vac, a prophylactic hepatitis B vaccine for adults, children, and newborns. It also engages in the development of VBI-2601 (BRII-179), an...
Running up then broke out premarket - then cliff hanger > then bounced to retest highs and exceeded NASDAQ:VBIV
Biotech company that I've analysed once in the past, and see it could hit a possible gain.
This one looks ready to bounce soon imo.
Gotta say I'm pretty stupid, and even a stupid person could tell this will spike up past recent highs on it's current trend. And with the Coronavirus, this company will probably be funded to work for it idk maybe.
Has reached its short term T.P. completing the CUP, may now do the "handle" retracement
On the watchlist VBI-1501 Phase 2 trial to start 1H 2020 Sci-B-Vac - CONSTANT Phase 3 data due early january BRII-179 (VBI-2601) Phase 2 data due 2H 2020
Entry level on breakout $1.42 = Target price $1.80 = Stop loss $1.32 Speculative breakout and gap fill trade VBI Vaccines, Inc. is a biopharmaceutical company, which engages in the development of vaccines for infectious disease and immuno-oncology. Its pipeline include HBV Therapeutic,HBV Prophylaxis, CMV Propylaxis, GBM Immunotherapy, MB Immunotherapy, and Zika...
VBI Vaccines, Inc. is a biopharmaceutical company, which engages in the development of vaccines for infectious disease and immuno-oncology. Its pipeline include HBV Therapeutic,HBV Prophylaxis, CMV Propylaxis, GBM Immunotherapy, MB Immunotherapy, and Zika Propylaxis. The company was founded on July 9, 2015 is headquartered in Cambridge, MA.
VBIV - WATCH - BIG buying by multiple key people. Resistance to break aroud 0.62.